Clinical Trial Search

Primary: Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS) — -0.89; 0.02; -0.47; -1.11 units on scale — p=<0.001

Primary: Rabies Virus Neutralizing Antibody Concentrations on Day 14. — 3.1; 3.3 IU/mL

Primary: Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring — -28.01; -24.79 Mean Number of Events

Primary: Percent Change From Baseline in Weekly Primary Generalized Tonic-clonic (PGTC) Seizure Frequency During the Entire Double-Blind Treatment Phase — 32.1; 75.4 percent…

Primary: Number of Randomized Participants Achieving Clinical Remission at Week 56 - Non-Responder Imputation (NRI) — 6; 9; 12 Participants — p=0.142

Primary: Bioequivalence of Implanon® and Radiopaque Implanon. — 2296; 2290; 5954; 6131 pg•month/mL — p=0.05

Primary: Median Progression Free Survival (PFS) in Months — 5.7; 5.8 Months

Primary: Change From Baseline in the Average AM Instantaneous (NOW) Total Nasal Symptom Score (TNSS) Averaged Over Days 2 to 15 — 9.83; 9.69; -2.36; -1.71 units on a scale…

Primary: Nankivell Glomerular Filtration Rate (GFR) — 24.56; 27.24; 59.04; 57.73 mL/min — p=0.575

Primary: The Rate of Confirmed Relapses During the Double-blind Phase (12 Months). — 0.28; 0.27 Number of relapses per patient — p=0.4859

Primary: Variance of Oral Bioavailability — 1.07; 0.74 ratio

Primary: Occurrence of Severe Clinical Rotavirus Disease Caused by Any Rotavirus Serotype More Than 14 Days Following the Third Dose — 79; 129; 38; 71 Subjects — p=<0.001

Primary: Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1) — -0.070; -0.035 L/yr

Primary: Mean Tracking Error Assessed During the Continuous Tracking Test (CTT) — 10.29; 12.49; 13.48 pixels — p=0.267

Primary: Treatment Outcome Score at 4 Hours Post-Dose — 49.5; 18.5 units on a scale — p=0.037